Rick Vreman works as a patient access manager and policy lead at Roche in the Netherlands. Originally trained as a pharmacist and health economist, he has worked on improving health technology assessment (HTA) policies and methodologies for 6 years at the National Health Care Institute (ZIN) as well as for Utrecht University as an assistant professor in the field of HTA. His field of expertise is Health Technology Assessment and access to medicines for patients. Specific topics are international HTA, the EU HTA Regulation, the Pharmaceutical legislation, unmet medical need, outcome-based reimbursement models, and real-world evidence.